Roche cobas EGFR Mutation Test, v2.0
Roche · Decision date Nov 4, 2026
What did the FDA approve?
FDA recorded an approval decision on 2026-11-04 for P120019/S045, a Special (Immediate Track) PMA supplement from Roche. The supplement covers updates to hazard information in the product labeling for the cobas® DNA Sample Preparation Kit, which the source describes as a component of the cobas® KRAS Mutation Test, cobas® BRAF V600 Mutation Test, and cobas® EGFR Mutation Test, v2.0. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename.
This action concerns labeling content for a shared sample-preparation component rather than a new approval of the broader test system; the source does not specify which hazard statements changed or which of the named tests the revised labeling affects. The device category is a somatic gene mutation detection system, specialty pathology, product code OWD. No supporting documents were included, so the revised label text and any clinical implications remain unknown from this record.
Readers should treat the decision as a labeling update only. The source gives no data on analytical or clinical performance, and no conclusion about test use or patient management follows from it.
FDA approval order statement
Approval for updates to the hazard information on the product labeling for cobas DNA Sample Preparation Kit, a component of cobas KRAS Mutation Test, cobas BRAF V600 Mutation Test, and cobas EFGR Mutation Test, v2.0.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Pathology
- Decision date
- Nov 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120019/S045
- Regulatory pathway
- PMA supplement
- Applicant
- Roche
- Product code
- OWD
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
For the original device and its historical approval scope, see PMA P120019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120019 · Original PMA
COBAS EGFR MUTATION TEST
P120019/S045 received
Application receipt date recorded by FDA.
P120019/S044 · Related supplement
cobas EGFR Mutation Test, v2.0
P120019/S045 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS EGFR MUTATION TESTP120019 | Roche | PMA approval | May 14, 2013 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588
Sources and methodology
- Original FDA record: P120019/S045
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



